Keyword Analysis & Research: dicerna pharmaceuticals
Keyword Research: People who searched dicerna pharmaceuticals also searched
Search Results related to dicerna pharmaceuticals on Search Engine
-
Novo Nordisk to Acquire Dicerna | Business Wire
https://www.businesswire.com/news/home/20211118005644/en/Novo-Nordisk-to-Acquire-Dicerna
Nov 18, 2021 · LEXINGTON, Mass.-- ( BUSINESS WIRE )-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will...
DA: 76 PA: 30 MOZ Rank: 32
-
News Details - Novo Nordisk
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=87435
Nov 18, 2021 · Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform. Bagsværd, Denmark, 18 November 2021 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a ...
DA: 77 PA: 63 MOZ Rank: 42
-
News Details - Novo Nordisk
https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=93736
Bagsværd, Denmark, 28 December 2021 – Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals (Dicerna), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a ...
DA: 73 PA: 95 MOZ Rank: 74
-
Dicerna Pharmaceuticals, Inc. | LinkedIn
https://www.linkedin.com/company/dicerna-pharmaceuticals-inc./
1,761 36 Comments. Dicerna Pharmaceuticals, Inc. | 30,568 followers on LinkedIn. Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid...
DA: 70 PA: 48 MOZ Rank: 65
-
Dicerna’s GalXC-Plus™ RNAi Technology Delivers ... - Business Wire
https://www.businesswire.com/news/home/20210330005357/en/Dicerna%E2%80%99s-GalXC-Plus%E2%84%A2-RNAi-Technology-Delivers-Target-Knockdown-Across-CNS-and-to-Specific-CNS-Cell-Types-in-Preclinical-Studies
Mar 30, 2021 · LEXINGTON, Mass.-- ( BUSINESS WIRE )-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi ...
DA: 26 PA: 26 MOZ Rank: 52
-
Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion
https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-novo-nordisk-buy-dicerna-pharma-33-billion-2021-11-18/
Nov 18, 2021 · Danish drugmaker Novo Nordisk has agreed a $3.3 billion cash deal to buy Dicerna Pharmaceuticals which specializes in therapeutics that counteract disease-causing genes, it said on Thursday.
DA: 99 PA: 55 MOZ Rank: 77
-
Dicerna Announces FDA Acceptance of Lilly’s Investigational New …
https://www.businesswire.com/news/home/20210527005186/en/Dicerna-Announces-FDA-Acceptance-of-Lilly%E2%80%99s-Investigational-New-Drug-IND-Application-for-LY3819469
May 27, 2021 · Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid ...
DA: 26 PA: 40 MOZ Rank: 54
-
Novo Nordisk to acquire biopharmaceutical company Dicerna for …
https://www.pharmaceutical-technology.com/news/novo-nordisk-acquire-dicerna/
Nov 19, 2021 · Novo Nordisk has signed a definitive agreement for the acquisition of Dicerna Pharmaceuticals, including its ribonucleic acid interference (RNAi) platform, for a total equity price of nearly $3.3bn in cash.
DA: 48 PA: 4 MOZ Rank: 28
-
Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To …
https://finance.yahoo.com/news/novo-nordisk-swallows-dicerna-3-142816889.html
Nov 18, 2021 · Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% ...
DA: 10 PA: 37 MOZ Rank: 68
-
Novo Nordisk completes acquisition of Dicerna Pharmaceuticals
https://www.drugdeliverybusiness.com/novo-nordisk-completes-acquisition-of-dicerna-pharmaceuticals/
Dec 28, 2021 · Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed. Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash ...
DA: 42 PA: 43 MOZ Rank: 33